nimodipine has been researched along with Cognition Disorders in 25 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nimodipine is a dihydropyridinic calcium antagonist with a role in neuroprotection, making it a promising therapy for vascular cognitive impairment and dementia." | 2.77 | Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE). ( Feng, T; Ju, Y; Shi, W; Wang, P; Wang, Y; Zhao, X; Zhou, Y, 2012) |
| "Recent data indicate that patients with vascular dementia (VaD) show a cholinergic deficit." | 2.71 | Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. ( Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M, 2004) |
| "Among these subtypes subcortical vascular dementia (SVD) may represent a well-defined entity in terms of pathophysiology, clinical features and neuroradiological aspects." | 2.71 | Therapy of vascular dementias. ( Basile, AM; Inzitari, D; Lamassa, M; Pantoni, L, 2004) |
| "One hundred and sixty patients with cerebral infarction were divided randomly into two groups." | 2.71 | [Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction]. ( Chen, Y; Li, J; Li, W; Shen, XH; Tang, XM; Wang, Y; Xia, X; Yuan, CX; Zhai, Y; Zheng, L, 2004) |
| "Vascular dementia is second most common cause of dementia." | 2.43 | [Pharmacological treatment of vascular cognitive impairment]. ( Bidzan, L, 2006) |
| "Pretreatment with nimodipine can lower the apoptosis rate of hippocampal neuron to reduce the incidence of postoperative cognitive dysfunction (POCD)." | 1.48 | Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats. ( Bao, Y; Gao, F; Guo, Y; Huo, S; Li, Y; Wang, Q; Wang, X; Xin, X; Yin, C; Zhang, Q, 2018) |
| "Following aneurysmal subarachnoid hemorrhage (SAH) many patients complain of and exhibit disturbances of a cognitive nature." | 1.27 | Does intravenous nimodipine treatment influence cognition in patients subjected to early aneurysm operation? ( Brandt, L; Ljunggren, B; Ryman, T; Säveland, H; Sonesson, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Li, Y | 1 |
| Bao, Y | 1 |
| Yin, C | 1 |
| Xin, X | 1 |
| Guo, Y | 1 |
| Gao, F | 1 |
| Huo, S | 1 |
| Wang, X | 1 |
| Wang, Q | 1 |
| Yan, J | 1 |
| Huang, Y | 1 |
| Lu, Y | 1 |
| Chen, J | 1 |
| Jiang, H | 1 |
| Yau, WY | 1 |
| Chu, E | 1 |
| Lai, N | 1 |
| Haile, M | 1 |
| Limson, F | 1 |
| Gingrich, K | 1 |
| Li, YS | 1 |
| Quartermain, D | 1 |
| Blanck, T | 1 |
| Bekker, A | 1 |
| Wang, P | 1 |
| Wang, Y | 3 |
| Feng, T | 1 |
| Zhao, X | 1 |
| Zhou, Y | 1 |
| Shi, W | 1 |
| Ju, Y | 1 |
| Corradini, I | 1 |
| Donzelli, A | 1 |
| Antonucci, F | 1 |
| Welzl, H | 1 |
| Loos, M | 1 |
| Martucci, R | 1 |
| De Astis, S | 1 |
| Pattini, L | 1 |
| Inverardi, F | 1 |
| Wolfer, D | 1 |
| Caleo, M | 1 |
| Bozzi, Y | 1 |
| Verderio, C | 1 |
| Frassoni, C | 1 |
| Braida, D | 1 |
| Clerici, M | 1 |
| Lipp, HP | 1 |
| Sala, M | 1 |
| Matteoli, M | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Cazzato, G | 1 |
| Griggio, S | 1 |
| Ukmar, M | 1 |
| Bava, A | 1 |
| Inzitari, D | 2 |
| Lamassa, M | 1 |
| Pantoni, L | 2 |
| Basile, AM | 1 |
| Zheng, L | 1 |
| Shen, XH | 1 |
| Li, W | 1 |
| Zhai, Y | 1 |
| Tang, XM | 1 |
| Yuan, CX | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Xia, X | 1 |
| Kobayashi, M | 1 |
| Masaki, T | 1 |
| Hori, K | 1 |
| Masuo, Y | 1 |
| Miyamoto, M | 1 |
| Tsubokawa, H | 1 |
| Noguchi, H | 1 |
| Nomura, M | 1 |
| Takamatsu, K | 1 |
| Koch, S | 1 |
| Gidal, BE | 1 |
| Wong, GK | 1 |
| Poon, WS | 1 |
| Wang, W | 1 |
| Wang, LN | 1 |
| Zhang, XH | 1 |
| Ma, L | 1 |
| Li, DJ | 1 |
| Bidzan, L | 1 |
| Vilkki, J | 2 |
| Ahola, K | 1 |
| Holst, P | 1 |
| Ohman, J | 1 |
| Servo, A | 1 |
| Heiskanen, O | 1 |
| Hütter, BO | 1 |
| Gilsbach, JM | 1 |
| Bergener, M | 1 |
| Carosi, M | 1 |
| Amigoni, S | 1 |
| Mascalchi, M | 1 |
| Meneses, A | 1 |
| Hong, E | 1 |
| Egge, A | 1 |
| Waterloo, K | 1 |
| Sjøholm, H | 1 |
| Solberg, T | 1 |
| Ingebrigtsen, T | 1 |
| Romner, B | 1 |
| Matula, C | 1 |
| Schoeggl, A | 1 |
| Norman, G | 1 |
| Brooks, SP | 1 |
| Hennebry, GM | 1 |
| Eacott, MJ | 1 |
| Little, HJ | 1 |
| Herrmann, WM | 1 |
| Stephan, K | 1 |
| Säveland, H | 1 |
| Sonesson, B | 1 |
| Ljunggren, B | 1 |
| Ryman, T | 1 |
| Brandt, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment[NCT03228498] | Phase 2 | 62 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for nimodipine and Cognition Disorders
| Article | Year |
|---|---|
[Pharmacological treatment of vascular cognitive impairment].
Topics: Animals; Cerebrovascular Disorders; Cognition Disorders; Dementia, Multi-Infarct; Dementia, Vascular | 2006 |
Treatment of cognitive disturbances in old age: methodological and clinical aspects.
Topics: Aged; Cognition Disorders; Humans; Nimodipine | 1993 |
Cerebral protection before, during and after neurosurgical procedures.
Topics: Amino Acids; Brain Damage, Chronic; Calcium Channel Blockers; Clinical Trials as Topic; Cognition Di | 2000 |
10 trials available for nimodipine and Cognition Disorders
| Article | Year |
|---|---|
Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cognition Disorders; Double-Blind Method; Female; Hu | 2012 |
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2004 |
Therapy of vascular dementias.
Topics: Aged; Brain; Cognition Disorders; Dementia, Vascular; Double-Blind Method; Humans; Hypertension; Int | 2004 |
[Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction].
Topics: Aged; Antihypertensive Agents; Blood Viscosity; Cerebral Infarction; Cognition Disorders; Drugs, Chi | 2004 |
[A nimodipine interventional study of patients with mild cognitive impairment].
Topics: Aged; Aged, 80 and over; Brain; Calcium Channel Blockers; Cognition; Cognition Disorders; Humans; Me | 2006 |
Prediction of psychosocial recovery after head injury with cognitive tests and neurobehavioral ratings.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Cognition Disorders; Discrimination Learning; Female | 1994 |
A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis.
Topics: Adult; Aged; Cerebrovascular Disorders; Cognition Disorders; Dementia, Vascular; Female; Humans; Mal | 1996 |
Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study.
Topics: Aged; Brain; Brain Ischemia; Cognition Disorders; Echoencephalography; Female; Fluid Therapy; Follow | 2001 |
Cognitive flexibility and mental programming after closed head injuries and anterior or posterior cerebral excisions.
Topics: Adolescent; Adult; Aged; Attention; Brain Damage, Chronic; Brain Neoplasms; Cognition Disorders; Fem | 1992 |
Efficacy and clinical relevance of cognition enhancers.
Topics: Acetylcarnitine; Clinical Trials as Topic; Cognition; Cognition Disorders; Dementia; Humans; Nimodip | 1991 |
12 other studies available for nimodipine and Cognition Disorders
| Article | Year |
|---|---|
Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats.
Topics: Aging; Animals; Apoptosis; Calcineurin; Calcium Channel Blockers; Cognition Disorders; Disease Model | 2018 |
Repeated administration of ketamine can induce hippocampal neurodegeneration and long-term cognitive impairment via the ROS/HIF-1α pathway in developing rats.
Topics: Analgesics; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calcium Channel Blockers; Carni | 2014 |
Cannabis, serotonergic drug use and stroke in a 50-year-old woman.
Topics: Cannabis; Cerebral Angiography; Cognition Disorders; Female; Headache Disorders, Primary; Humans; Ma | 2015 |
Nimodipine prevents transient cognitive dysfunction after moderate hypoxia in adult mice.
Topics: Animals; Attention; Blood Gas Analysis; Calcium Channel Blockers; Calcium Channels, L-Type; Cognitio | 2009 |
Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs.
Topics: Animals; Anticonvulsants; Association Learning; Brain; Carbamazepine; Cognition Disorders; Epilepsy; | 2014 |
Hippocalcin-deficient mice display a defect in cAMP response element-binding protein activation associated with impaired spatial and associative memory.
Topics: Animals; Association Learning; Avoidance Learning; Behavior, Animal; Blotting, Western; Brain; Cadmi | 2005 |
Phenytoin and cognitive decline.
Topics: Anticonvulsants; Area Under Curve; Calcium Channel Blockers; Cognition Disorders; Cytochrome P-450 E | 2005 |
Use of phenytoin and other anticonvulsant prophylaxis in patients with aneurysmal subarachnoid hemorrhage.
Topics: Cognition Disorders; Drug Interactions; Humans; Intracranial Aneurysm; Nimodipine; Phenytoin; Seizur | 2005 |
Which neuropsychological deficits are hidden behind a good outcome (Glasgow = I) after aneurysmal subarachnoid hemorrhage?
Topics: Adult; Age Factors; Aphasia; Cognition Disorders; Female; Follow-Up Studies; Glasgow Coma Scale; Hum | 1993 |
Spontaneously hypertensive rats: a potential model to identify drugs for treatment of learning disorders.
Topics: Aging; Analysis of Variance; Animals; Blood Pressure; Calcium Channel Blockers; Cognition Disorders; | 1998 |
Nimodipine prevents scopolamine-induced impairments in object recognition.
Topics: Animals; Calcium Channel Blockers; Cognition Disorders; Dose-Response Relationship, Drug; Explorator | 2002 |
Does intravenous nimodipine treatment influence cognition in patients subjected to early aneurysm operation?
Topics: Adult; Aged; Cognition Disorders; Humans; Injections, Intravenous; Middle Aged; Neuropsychological T | 1988 |